# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frédéric Chopin (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI020-SYN
- Date: 2026-04-07
- Fictional facility: St. Posthumous Health Center
- Fictional author: Matthias Lindqvist, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-and-a-half-week review: release from isolation, return to teaching, liver tests, and tests for the alternatives. **S**

## History of present illness

Mr. Chopin returns after nineteen days of treatment, all observed by video. The night sweats stopped in the second week, he has had no fever for ten days and no blood in his sputum for twelve, and his cough is now occasional. He had mild nausea in the first week, eased by taking the tablets in the middle of breakfast, and his urine and tears are orange as expected. He has no tendon pain, tingling, yellowing, dark urine, or rash. The three sputum smears collected in the third week were all negative, and the health department released him from isolation two days ago; he will start teaching in his studio again this week, beginning with eight lessons. The baseline cultures are growing Mycobacterium tuberculosis complex, and the molecular tests show no mutations for isoniazid or fluoroquinolone resistance. He has seen the dietitian twice and drinks two supplements a day in the afternoon and evening. His mood is better now that he can see his students. The sweat chloride test was done this morning. **S**

| Element | Detail |
|---|---|
| Treatment | Nineteen of nineteen doses observed |
| Infection control | Three negative smears; released from isolation; teaching again this week |
| Microbiology | Cultures growing M. tuberculosis complex; no isoniazid or fluoroquinolone resistance mutations |
| Weight | 49.6 kg, up 1.1 kg |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Occasional cough; no blood for twelve days |
| Constitutional | Negative | No fever or night sweats; appetite returning |
| Gastrointestinal | Negative | Nausea gone; no abdominal pain or jaundice |
| Musculoskeletal | Negative | No tendon or joint pain |
| Neurological | Negative | No numbness or tingling |
| Psychiatric | Negative | Mood better; no thoughts of suicide or self-harm |

6 systems reviewed. **S**

## Current medications

- Rifapentine 150 mg tablets, eight tablets (1200 mg) daily with food **S**
- Moxifloxacin 400 mg tablet, one tablet daily **S**
- Isoniazid 300 mg tablet, one tablet daily **S**
- Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily **S**
- Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 106/66 mmHg; pulse 86 bpm; respirations 16/min; temperature 37 °C; oxygen saturation 97% on room air; weight 49.6 kg; BMI 17.2 kg/m². All vital signs are synthetic.

ALT: 34 U/L; AST: 31 U/L; Total bilirubin: 0.8 mg/dL; Sweat chloride: 18 mmol/L; Alpha-1 antitrypsin: 142 mg/dL. All results are synthetic.

## Change since baseline

- ALT: 18 U/L at baseline, 34 U/L at this visit **S**
- AST: 24 U/L at baseline, 31 U/L at this visit **S**
- Total bilirubin: 0.5 mg/dL at baseline, 0.8 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Thin, brighter; weight 49.6 kg; temperature 37.0 °C |
| Eyes | No icterus |
| Respiratory | A few crackles at the right apex; no bronchial breathing |
| Musculoskeletal | Tendons non-tender |
| Neurological | Normal sensation in the fingers and feet |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Pulmonary tuberculosis, intensive phase** (A15.0). Good early response with sputum smear conversion. Liver tests normal (ALT 34, AST 31, bilirubin 0.8). No isoniazid or fluoroquinolone resistance on molecular testing; phenotypic susceptibility pending. **S**
   - Continue the four drugs and pyridoxine daily by video with breakfast.
   - Monthly sputum culture: the samples from the third week are the first.
   - Back to teaching with the health department's agreement; no mask is needed now.
2. **Cystic fibrosis and alpha-1 antitrypsin deficiency**. Sweat chloride 18 mmol/L, below 30, so cystic fibrosis is unlikely; alpha-1 antitrypsin 142 mg/dL, normal, so severe deficiency is excluded. With the CT showing no bronchiectasis or emphysema, neither explains his illness; tuberculosis does. **S**
   - No further testing for either.
3. **Moderate protein-calorie malnutrition** (E44.0). Weight rising with treatment and supplements. **S**
   - Continue the dietitian's plan.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, hemoptysis, fever, night sweats | Every visit | Completed today | Occasional cough; no fever, sweats, or blood |
| Examination | Weight, with the pyrazinamide dose checked against the weight band | Monthly | Completed today | 49.6 kg; pyrazinamide band unchanged |
| Medication safety | Adverse effects: hepatitis symptoms, tendon pain, numbness or tingling, rash, nausea, orange body fluids | Every visit | Completed today | Early nausea resolved; no tendon pain, tingling, rash, or jaundice |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline; repeat for symptoms or risk factors (here at two to three weeks, for low weight and albumin) | Completed today | ALT 34, AST 31 U/L, bilirubin 0.8 mg/dL, all normal |
| Laboratory | Sputum acid-fast smear and culture | Baseline, then monthly until two consecutive cultures are negative | Completed today | Three smears in the third week negative; baseline cultures growing M. tuberculosis complex; third-week cultures pending |
| Laboratory | Rapid molecular testing for isoniazid and fluoroquinolone resistance | At baseline | Completed today | No isoniazid (katG, inhA) or fluoroquinolone (gyrA, gyrB) resistance mutations |
| Laboratory | Phenotypic susceptibility (rifampin, isoniazid, pyrazinamide, moxifloxacin) | At baseline | Ordered | Set up on the baseline isolate; pending |
| Medication safety | Doses observed and the completion clock (56 doses within 70 days, 63 within 84 days, 119 within five months) | Every visit | Completed today | Nineteen of nineteen doses observed |
| Self-management | Home airborne isolation and the release criteria | Until three negative smears, clinical improvement, and two weeks of treatment | Completed today | Release criteria met; released by the health department two days ago |
| Referral | Contact investigation (students, friends, close contacts) | Led by the health department from diagnosis | Referred | In progress with the health department; no results in his record |
| Self-management | Nutrition: dietitian, intake, supplement drinks | Every visit until weight is restored | Completed today | Two dietitian visits; two supplement drinks a day, apart from the dose |
| Laboratory | Sweat chloride and serum alpha-1 antitrypsin | Once, to address the alternatives | Completed today | Sweat chloride 18 mmol/L; alpha-1 antitrypsin 142 mg/dL; both normal |
| Survey | Depression screen (PHQ-9) | At diagnosis, at two months, and at the end of treatment | Not indicated | Next at two months; mood better today |

## Goal progress

- Complete all 119 doses within five months by video-observed therapy. In progress; target 2026-07-21. **S**
- Sputum culture negative at two months. In progress; target 2026-07-21. **S**
- Return to teaching once the health department confirms he is no longer infectious. Outcome by 2026-04-07: Released from isolation after three negative smears and more than two weeks of treatment; teaching again from the third week. **S**
- Weight back to at least 55 kg by the end of treatment. In progress; target 2026-07-21. **S**
- PHQ-9 below 5 by the end of treatment. In progress; target 2026-07-21. **S**

## Guideline basis

- Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016), American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America (Clinical Infectious Diseases)
- Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR)
- An official ATS statement: hepatotoxicity of antituberculosis therapy (2006), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine)
- Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation (2017), Cystic Fibrosis Foundation (Journal of Pediatrics)
- American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency (2003), American Thoracic Society and European Respiratory Society (American Journal of Respiratory and Critical Care Medicine)
- Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012), Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition (JPEN)

## Follow-up

- End-of-intensive-phase review in about five weeks, with the two-month sputum culture, liver tests, a blood count, and the PHQ-9. **S**
- Next scheduled visit 2026-05-15: end of the eight-week intensive phase: susceptibility results, the two-month sputum culture, and the start of the continuation phase. **S**
